I just had my latest scans, and I am still stable with my current treatment plan- Lynparza, Lupron, Xgeva. In fact, the scan said "no evidence of metastatic disease in the abdomen"- I had tumors in the liver we were monitoring. I ask my MO if there was any way to monitor molecular progression- progression before it is large enough to show on a scan. He said for me to read up on the Signatera test and let him know if I wanted to do that test.
As you can see from my profile, I got 4 years out of Ibrance before I had progression. And I am 3+ years on Lynparza as my second line therapy.
My question to the group is - have any of you read the research about using the circulating tumor DNA testing outside of when you have progression and trying to decide on the next line of therapy? Instead, just using the test to monitor the stability of the disease. What does the research say about changing treatment based on the ctDNA results versus the scan results?
I do not do tumor markers, as they are unreliable in my case. My history showed elevated TM's, but not too elevated even when I had large tumors in the liver. And they only dropped a few points when the tumors shrunk.
I just don't know if I want to do the Signatera testing if it would not give good information (waste of money), and if I should move to another treatment if the Signatera testing suggested it but yet I still have stable scans.
Thoughts….